2月25日，爱博诺德（北京）医疗科技股份有限公司（简称"爱博医疗"）正式宣告跨界切入运动医学赛 道。公告显示，爱博医疗拟以6.83亿元对价，使用并购贷款及自有资金收购德美联合（重庆）医疗科技 有限公司（简称"德美医疗"）68.31%股权。 挑战与机遇并存 对于爱博医疗而言，控股德美医疗既是跨界突围的重要一步，也面临着多重挑战。从行业竞争来看，运 动医学赛道虽潜力巨大，但竞争已日趋激烈，除了施乐辉、强生等外资龙头占据较高市场份额外，国内 也涌现出天星医疗、杭州锐健等优秀企业，德美医疗虽位列国产前三，但要实现进一步突破，仍需持续 的研发投入和市场推广支持。 从自身业务来看，爱博医疗的眼科主业仍需持续发力。为应对集采冲击，爱博医疗在2025年推出了两款 新产品，其中，用于成年人近视矫正的有晶体眼人工晶状体"龙晶PR"目前仍处于市场推广阶段；角膜 塑形镜业务虽呈现回暖态势，2025年第三季度实现双位数增长，但仍难以完全抵消人工晶状体业务的利 润下滑压力。 此次股权收购，双方还设定了业绩承诺，2026年至2028年，德美医疗年度净利润分别不低于4500万元、 5500万元、6500万元，三年累计不低于1.65亿元，若未 ...

抗凝药物升级窗口已至，下一代药物箭在弦上 国泰海通发布研报称，人口老龄化与心血管疾病患病率攀升推动抗血栓药物市场持续扩容，其中抗凝药 物作为核心品类，市场需求稳步增长，中国市场增速尤为显著，为新型抗凝药物研发与商业化奠定了广 阔的市场基础。凭借"精准抗凝、低出血风险"的独特优势，FXI成为下一代抗凝药的理想靶点，目前全 球有多款FXI/FXIa抑制剂进入注册性临床阶段，涵盖小分子、大分子单抗、siRNA等多种技术路线，覆 盖房颤、卒中预防、静脉血栓栓塞等多个适应症。 国泰海通主要观点如下： 抗血栓药物市场需求扩容，格局待新 血栓性疾病成为全球主要死亡原因之一，人口老龄化与心血管疾病患病率攀升推动抗血栓药物市场持续 扩容，2023年全球市场规模已达529亿美元，预计2033年将突破1100亿美元。其中抗凝药物作为核心品 类，市场需求稳步增长，中国市场增速尤为显著，为新型抗凝药物研发与商业化奠定了广阔的市场基 础。 2)大分子FXI单抗中，诺华的Abelacimab已获得FDA两项快速通道资格，分别针对房颤卒中预防及肿瘤 相关血栓，目前正在推进III期临床；再生元双管线布局FXI单抗，直接阻断FXI的催化结构域的 ...

从靶点到管线，FXI 引领抗凝产业新变革 [Table_Industry] 医药 FXI/FXIa 抑制剂行业研究报告 | [Table_Invest] | | | --- | --- | | 评级： | 增持 | | | | | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 彭娉(分析师) | 021-23185619 | pengping@gtht.com | S0880525040080 | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | 本报告导读： 靶向 FXI 的药物可在不显著增加出血风险的前提下防治血栓，有望为患者提供更安 全的抗凝选择。当前该领域的研发活跃，2026 年起预计有多个药物进入关键数据读 出的阶段，静待抗凝领域新一代"大药"的诞生。 投资要点： [Table_Report] 相关报告 医药《医疗设备招采规模高基数影响部分回落， 关注手术机器人市场机遇》2026.02.09 医药《高景气延续，持续推荐创新药械产业链》 2 ...

Company Performance - Johnson & Johnson (JNJ) reported a total revenue of $94.193 billion for 2025, representing a year-on-year growth of 6%, with Q4 revenue reaching $24.56 billion, up 9.1% year-on-year, both exceeding market expectations [1] - The company provided guidance for 2026 revenue between $99.5 billion and $100.5 billion, with adjusted earnings per share expected to be between $11.43 and $11.63, also above Wall Street consensus [1] - The oncology business, including CAR-T therapy Carvykti, saw a significant revenue increase of 95.9%, while the immunology business experienced an 11.8% decline due to patent expirations of products like Stelara [3] Industry Policy and Environment - On February 12, 2026, major U.S. stock indices fell collectively, with the Dow Jones down 1.34% and the Nasdaq down 2.03%, while the pharmaceutical sector rose by 1.87%, indicating a cautious market sentiment [2] - As of February 2026, 57% of 28 institutions rated Johnson & Johnson as "buy" or "hold," with a target average price of $237.48, slightly below the current stock price, suggesting some investors are inclined to take profits [2] Financial and Technical Aspects - On February 12, Johnson & Johnson's stock price had a volatility of 2.77%, with a trading volume of approximately $2.51 billion, indicating increased divergence between bulls and bears [4] - The stock reached an intraday high of $246.35, close to its historical peak, but failed to break through, potentially due to technical resistance and profit-taking trends favoring defensive sectors [4] Summary - Despite exceeding performance expectations, Johnson & Johnson's stock is constrained by industry differentiation, macroeconomic pressures, and technical factors, preventing a short-term breakthrough of historical highs [5]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The commercialization of ADC (Antibody-Drug Conjugates) is accelerating, with 20 ADC drugs approved globally, and 6 of them have been in the "billion-dollar club" for two consecutive years [30][31] - The report highlights the increasing competition in the ADC sector, with approximately 60 ADC drugs currently in clinical phase 3 and application stages [30] - Domestic innovative pharmaceutical companies are adopting various strategies for ADC capacity layout, with companies like Rongchang Biopharma transitioning from outsourcing to in-house production, while others like Kelong Biotechnology are building their own production bases [31][32] Summary by Sections Market Review - The pharmaceutical index rose by 0.14% this week, outperforming the CSI 300 index by 1.47 percentage points, ranking 15th in industry performance [10] - Year-to-date, the pharmaceutical index has increased by 3.28%, also outperforming the CSI 300 index by 2.99 percentage points, ranking 23rd [10] Individual Stock Performance - In the A-share market, 255 out of 479 pharmaceutical stocks rose, with the top five performers being Guangshengtang (+29.83%), Haixiang Pharmaceutical (+18.64%), and Meidixi (+18.04%) [20] - In the Hong Kong market, 38 out of 116 pharmaceutical stocks rose, with the top performers including Yiteng Jiahe (+14%) and Kedi-B (+9.96%) [24] Industry News and Policies - The newly revised "Regulations on the Implementation of the Drug Administration Law" supports segmented contract manufacturing and commercial-scale drug sales, providing a foundation for ADC commercialization cooperation [32] - Notable industry developments include Novartis's application for Ianalumab in China and Johnson & Johnson's approval of Daratumumab injection for multiple myeloma treatment [27][28] Weekly Insights - The ADC commercialization battle has begun, with a significant increase in demand for ADC production capacity, leading to a supply-demand imbalance [30] - Major CXO companies are expanding ADC production capacity, with companies like WuXi AppTec acquiring East Yao Pharmaceutical to meet rising orders [31]

Core Insights - Boston Scientific reported Q4 2025 revenue of $5.286 billion, a 15.9% year-over-year increase, exceeding market expectations of $5.280 billion [27][32] - The electrophysiology segment, which was highly anticipated, generated $890 million in sales, falling short of the market expectation of $933 million, leading to a stock price drop of over 17% [28][19] - The company's overall performance was strong, but the market reacted negatively due to concerns over the sustainability of growth driven by a single segment [19][48] Financial Performance - Q4 2025 revenue: $5.286 billion, up 15.9% YoY [32] - GAAP net profit: $672 million, up 18.7%, with earnings per share of $0.45 [32] - Adjusted EPS: $0.80, exceeding the company's guidance of $0.77-$0.79 [32] - Full-year revenue surpassed $20 billion for the first time, with a 19.9% YoY increase [33] Segment Performance - Cardiovascular segment revenue: $3.477 billion, up 18.2%, the strongest performing segment [32] - Electrophysiology segment growth was 35% in Q4, but analysts expressed concerns over the sustainability of this growth [44][39] - The Watchman device, another flagship product, reported $535 million in revenue, missing expectations by $4 million, indicating potential market saturation [45][44] Market Dynamics - The electrophysiology segment is critical to Boston Scientific's growth narrative, with the PFA technology previously showing explosive growth [37][39] - Competition is intensifying with the entry of Medtronic's PulseSelect and Johnson & Johnson's Varipulse, which may erode Boston Scientific's market share [41][43] - The U.S. market for PFA technology is experiencing a transition phase, which may limit future growth as initial conversions to PFA have been completed [39] Future Outlook - The company anticipates organic revenue growth of 10-11% for 2026, a significant slowdown from 15.8% in 2025 [49][48] - Management remains confident in maintaining market leadership in electrophysiology, with plans for product innovation and expansion into new indications [54] - International markets, particularly in China and Japan, present significant growth opportunities as they are still in early stages of PFA technology adoption [54]

手术机器人行业深度报告：AI 驱动辅助操作迈向"自动驾 驶" ，国产龙头扬帆全球市场 20260201 手术机器人行业具备多个显著优势，使其成为当前医疗器械领域最具吸引力的 商业模式之一。首先，手术机器人结合了设备、耗材和服务模式，带来高粘性 和持续现金流。一旦设备装机入院，就能在医院中占据重要位置，持续贡献稳 定现金流。此外，手术机器人不仅是耗材的流量入口，还在数据方面具有高价 值，并能带来耗材品类升级及数据服务等商业机会。 从市场渗透率和增长空间 来看，目前手术机器人的渗透率仍较低，尤其是在腔镜、骨科、泛血管、消化 道、经皮穿刺、神经外科及齿科等领域都有巨大增长潜力。同时，在全球范围 内，主要市场集中于美国和欧洲等发达地区，新兴市场需求尚未被充分挖掘。 结合全球 AI 技术的发展趋势，我们预计 AI 将进一步赋能手术机器人，使其逐 步实现类似自动驾驶的终极形态。目前，包括直觉外科在内的多家公司，以及 国内如微创机器人、金风医疗和天智航等企业，都在 AI 领域进行前瞻布局。 中国腔镜机器人渗透率远低于美国，但腹腔镜手术量巨大，未来市场潜 力巨大。腔镜机器人技术核心在于灵活操作，骨科机器人则侧重精准规 划。 ...

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The focus remains on the combination of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates), with significant advancements expected in their joint application [10][11] - The year 2026 is identified as a critical year for the combination of IO and ADC, with expectations for increased demand for ADCs, particularly in the context of various cancer treatments [11][41] Summary by Sections Section 1: Focus on Second-Generation IO and ADC - Merck's sac-TMT is a strategic focus, with 16 ongoing Phase III clinical trials, particularly in gynecological cancers [14][15] - AstraZeneca has 8 ADCs in clinical stages, with significant data readouts expected in 2026 [19][20] - Pfizer is advancing 4 Phase III clinical trials for its PD-1/VEGF dual antibody SSGJ-707, highlighting its strategic importance in oncology [26][27] - Johnson & Johnson aims to become the leading oncology company by 2030, focusing on multiple myeloma and various cancers [30] - Bristol-Myers Squibb (BMS) is advancing its PD-L1/VEGF dual antibody and oral CELMoD therapies, with significant data catalysts expected in 2026 [32][33] - Roche is focusing on breast cancer, with its oral SERD Giredestrant expected to be approved soon [37][38] Section 2: The Year of IO+ADC Combination - The combination of IO and ADC is seen as a key development direction, with various clinical trials underway [41] - The first-generation IO+ADC combinations are competitive, with sac-TMT emerging as a significant player [42] - The second-generation IO combined with chemotherapy is led by AK112, with multiple milestones expected in the coming years [47] - The second-generation IO combined with ADC is still in early exploration, with AstraZeneca leading the way [49] Section 3: Investment Recommendations and Targets - The report identifies several investment targets, including Kangfang Biotech, 3SBio, and others, highlighting their potential in the oncology sector [11][56]

Core Insights - The JPMorgan Global Healthcare Conference serves as a significant platform for the biopharmaceutical industry, influencing capital flows and industry dynamics for the year ahead [1] - This year's conference highlighted the increasing presence of Chinese biotech companies, marking a shift from being mere spectators to key players in the global market [2][3] Group 1: Chinese Biotech Companies - Seven Chinese companies, including WuXi AppTec and BeiGene, presented on the main stage, with an additional 17 companies showcasing in the Asia-Pacific session [2] - The transformation of Chinese companies from the periphery to the center of the conference reflects their substantial innovation value, evidenced by numerous licensing deals announced during the event [3] Group 2: Licensing Deals and Collaborations - Notable licensing agreements included a $650 million upfront payment from AbbVie to Rongchang Biopharma for the global rights to its PD-1/VEGF dual-specific antibody, with a total potential deal value of up to $5.6 billion [3] - Other significant collaborations involved Zhongsheng Peptide and Sai Shen Pharmaceutical partnering with Novartis, with the latter's deal valued at approximately $1.665 billion [3] Group 3: MNCs and Market Dynamics - The cautious approach of multinational corporations (MNCs) towards acquisitions is driven by the impending "patent cliff," with over $320 billion in market potential products set to lose patent protection in the next decade [3][5] - MNCs are increasingly favoring "asset-based acquisitions" over full company buyouts, allowing them to efficiently acquire core assets without the burdens of integrating entire companies [4] Group 4: AI in Drug Development - AI's integration into drug development emerged as a central theme, with Eli Lilly and NVIDIA announcing a partnership to establish a $1 billion AI innovation lab aimed at addressing long-standing challenges in the pharmaceutical industry [5][6] - The acquisition of Modella AI by AstraZeneca further emphasizes the growing importance of AI in enhancing drug discovery and clinical development processes [6] Group 5: Future Outlook - The 2026 JPM conference is expected to reflect a new paradigm where Chinese innovation becomes essential, and AI evolves from a supportive tool to a foundational infrastructure in drug development [8][9]

在这一年的交易热潮中，跨国巨头们的采购风格各有不同。谁出手频次最高？谁手笔最大？经济观 察报分析了全年150多笔交易，复盘跨国药企的投资画像与交易特色。 多位受访者对经济观察报表示，其所在药企与潜在合作方达成了进一步沟通意向，他们判断2026 年中国创新药对外授权交易热仍会持续。 2025年爆发式增长的对外授权交易验证了中国创新药资产的价值，该年对外授权总交易额超1300 亿美元，交易数超150笔（约占全球40%），创下历史新高。 阿斯利康最活跃 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共出手了5次。 合作方包括石药集团（01093.HK）、和铂医药（02142.HK）、加科思药业（01167.HK）、元 思生肽等。其中，在2025年6月与石药集团达成的潜在总交易额超53亿美元的合作，可排进年度 交易额前四。在资产选择上，阿斯利康主要集中在临床早期管线，以及技术平台合作。 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共 出手了5次。从立即兑现的首付款看，辉瑞与武田制药出手最 阔绰。 作者：张英 封图：图虫创意 作为中国市场销售额最高的外资药企，在经历2024年的公司治理风暴后，阿斯利康 ...